Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dotan, N
Right arrow Articles by Dukler, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dotan, N
Right arrow Articles by Dukler, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 15, No. 7, 442-450 (2006)
DOI: 10.1191/0961203306lu2331oa

Anti-Glycan Antibodies as Biomarkers for Diagnosis and Prognosis

N Dotan

Glycominds Ltd, Lod, Israel, nirdo{at}glycominds.com

RT Altstock

Glycominds Ltd, Lod, Israel

M Schwarz

Glycominds Ltd, Lod, Israel

A Dukler

Glycominds Ltd, Lod, Israel

Glycans (sugars or carbohydrates) are predominant surface components of cells such as erythrocytes, immune cells and microorganisms. As such, they give rise to high levels of anti-glycan antibodies of all classes. Antibodies to certain defined mono, di and oligosaccharides that are common in bacterial, fungal and parasite cells exist in human sera and can be profiled using glycan arrays. The use of glycan arrays for systematic screening of blood samples from multiple sclerosis (MS) and Crohn’s disease (CD) patients in versus to blood samples from control groups, have lead to the discovery of a few anti glycan antibodies biomarkers enabling diagnosis and prognosis in MS and CD patients. Anti-Glc({alpha}1,4)Glc({alpha}) IgM antibodies were found to be specific for MS patients, enabling differentiation between MS patients and patients with other neurological diseases, with 54% sensitivity and 85% specificity. Anti-Glc({alpha}1,4)Glc({alpha}) IgM were found to be predictive for the conversion of patients in first acute neurological event to clinically defined MS. Anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-chitobioside (ACCA) antibodies were found to be specific for CD. The combined use of these antibodies enables improved diagnosis of CD versus ulcerative colitis and other gastrointestinal diseases, as well as stratification of CD patients with a more complicated disease and high risk for surgery. Anti-glycan antibodies profiling (AGAP) is a new and promising approach for development of biomarkers for diagnosis and prognosis.

Key Words: antibodies • Crohn’s disease • diagnosis • glycan-array • multiple sclerosis • prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-C. Wang, Y.-L. Huang, C.-T. Ren, C.-W. Lin, J.-T. Hung, J.-C. Yu, A. L. Yu, C.-Y. Wu, and C.-H. Wong
Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer
PNAS, August 19, 2008; 105(33): 11661 - 11666.
[Abstract] [Full Text] [PDF]